Upon resistance to EGFR inhibition by monoclonal antibodies, cancer cells display a rewiring of feedback production, with an upregulation of genes that are able to sustain the signal and a downregulation of genes intrinsically able to dampen the EGFR pathway. This evidence concerns the gene EGFR and cancer.